Skip to Main Content
Back to News

Insider Sale: President of R&D of $SDGR Sells 8,378 Shares

Automated

Karen Akinsanya, the President of R&D of $SDGR, sold 8,378 shares of the company on 04-14-2025 for an estimated $210,390. We received data on the trade from a recent SEC filing. This was a sale of approximately 25.9% of their shares of this class of stock. Following this trade, they now own 23,970 shares of this class of $SDGR stock.

$SDGR Insider Trading Activity

$SDGR insiders have traded $SDGR stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $SDGR stock by insiders over the last 6 months:

  • KAREN AKINSANYA (President of R&D, Therapeutics) has made 0 purchases and 3 sales selling 16,723 shares for an estimated $419,570.
  • YVONNE TRAN (EVP, CLO & CPO) has made 0 purchases and 2 sales selling 4,730 shares for an estimated $129,484.
  • GEOFFREY CRAIG PORGES (EVP & CFO) sold 5,491 shares for an estimated $119,484
  • JENNY HERMAN (SVP & Controller) has made 0 purchases and 2 sales selling 1,525 shares for an estimated $35,044.
  • ROBERT LORNE ABEL (See Remarks) sold 1,225 shares for an estimated $31,837
  • MARGARET DUGAN (Chief Medical Officer) sold 1,531 shares for an estimated $27,225
  • KENNETH PATRICK LORTON (EVP, CTO & COO, Software) sold 985 shares for an estimated $24,063

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SDGR Hedge Fund Activity

We have seen 92 institutional investors add shares of $SDGR stock to their portfolio, and 102 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$SDGR Analyst Ratings

Wall Street analysts have issued reports on $SDGR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • BMO Capital issued a "Outperform" rating on 11/13/2024

To track analyst ratings and price targets for $SDGR, check out Quiver Quantitative's $SDGR forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles